| Title: |
Prognostic Impact of Serum β 2 -Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients |
| Authors: |
Theodoros P. Vassilakopoulos; Maria Arapaki; Panagiotis T. Diamantopoulos; Athanasios Liaskas; Fotios Panitsas; Marina P. Siakantaris; Maria Dimou; Styliani I. Kokoris; Sotirios Sachanas; Marina Belia; Chrysovalantou Chatzidimitriou; Elianna A. Konstantinou; John V. Asimakopoulos; Kyriaki Petevi; George Boutsikas; Alexandros Kanellopoulos; Alexia Piperidou; Maria-Ekaterini Lefaki; Angeliki Georgopoulou; Anastasia Kopsaftopoulou; Kalliopi Zerzi; Ioannis Drandakis; Maria N. Dimopoulou; Marie-Christine Kyrtsonis; Panayiotis Tsaftaridis; Eleni Plata; Eleni Variamis; Gerassimos Tsourouflis; Flora N. Kontopidou; Kostas Konstantopoulos; Gerassimos A. Pangalis; Panayiotis Panayiotidis; Maria K. Angelopoulou |
| Source: |
Cancers, Vol 16, Iss 2, p 238 (2024) |
| Publisher Information: |
MDPI AG |
| Publication Year: |
2024 |
| Collection: |
Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: |
Hodgkin’s lymphoma; β 2 -microglobulin; prognostic factors; chemotherapy; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282 |
| Description: |
The significance of serum beta-2 microglobulin (sβ 2 m) in Hodgkin lymphoma (HL) is controversial. We analyzed 915 patients with HL, who were treated with ABVD or equivalent regimens with or without radiotherapy. Sβ 2 m levels were measured by a radioimmunoassay (upper normal limit 2.4 mg/L). Sequential cutoffs (1.8–3.0 by 0.1 mg/L increments, 3.5 and 4.0 mg/L) were tested along with ROC analysis. The median sβ 2 m levels were 2.20 mg/L and were elevated (>2.4 mg/L) in 383/915 patients (41.9%). Higher sβ 2 m was associated with inferior freedom from progression (FFP) at all tested cutoffs. The best cutoff was 2.0 mg/L (10-year FFP 83% vs. 70%, p = 0.001), which performed better than the 2.4 mg/L cutoff (“normal versus high”). In multivariate analysis, sβ 2 m > 2.0 mg/L was an independent adverse prognostic factor in the whole patient population. In multivariate overall survival analysis, sβ 2 m levels were predictive at 2.0 mg/L cutoff in the whole patient population and in advanced stages. Similarly, sβ 2 m > 2.0 mg/L independently predicted inferior HL-specific survival in the whole patient population. Our data suggest that higher sβ 2 m is an independent predictor of outcome in HL but the optimal cutoff lies within the normal limits (i.e., at 2.0 mg/L) in this predominantly young patient population, performing much better than a “normal versus high” cutoff set at 2.4 mg/L. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://www.mdpi.com/2072-6694/16/2/238; https://doaj.org/toc/2072-6694; https://doaj.org/article/9df59c400a34426ab40a783347a11f2b |
| DOI: |
10.3390/cancers16020238 |
| Availability: |
https://doi.org/10.3390/cancers16020238; https://doaj.org/article/9df59c400a34426ab40a783347a11f2b |
| Accession Number: |
edsbas.CEEAF6B3 |
| Database: |
BASE |